Immucell (ICCC) Other financing activities (2010 - 2023)

Immucell (ICCC) has reported Other financing activities for 13 consecutive years, with $1.0 million the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Other financing activities changed N/A year-over-year to $1.0 million; the trailing twelve-month figure through Dec 2025 stood at $1.0 million (changed 0.0% YoY), and the FY2025 full-year result was $3.0, changed N/A from the prior year.
• Other financing activities advanced to $1.0 million in Q1 2023 per ICCC's latest filing, from -$2.0 in the prior quarter.
• Across five years, Other financing activities topped out at $8.3 million in Q1 2019 and bottomed at -$2.0 in Q4 2022.
• Historically, Other financing activities has averaged $1.6 million across 4 years, with a median of $90437.0 in 2021.
• The widest YoY moves for Other financing activities: up 199693.94% in 2019, down 199693.94% in 2019.
• Over 4 years, Other financing activities stood at $8.3 million in 2019, then plunged by 99.06% to $78430.0 in 2021, then sank by 100.0% to -$2.0 in 2022, then jumped by 50000100.0% to $1.0 million in 2023.
• According to Business Quant data, Other financing activities over the past three periods registered $1.0 million, -$2.0, and $78430.0 for Q1 2023, Q4 2022, and Q3 2021 respectively.